The Microbiome is one of the hottest areas of personalized medicine being studied. Experts in pharma, biotech, and investors are checking out how they can be a part of this emerging space - and what discoveries are next.
Clinical development and research in multiple therapeutic areas, including allergies, infant health, and microbiome discovery and application beyond the gut.
Learn what is being done to steer the relevance and future direction of the human microbiome frontier.
This session will cover studies on early life microbiome development, especially the part of the microbiome that concern fungi n pre-term children, and correlated fungal and bacterial composition to health risks such as NEC and sepsis. This will cover findings in the implication of pre-term birth, the extensive use of antibiotics in early life, and fungi composition in the early life intestinal compartment, highlighting the mechanistic elements of fungi-epithelial function which is relevant for later risks of immune mediated chronic diseases in adulthood.
This session will also consider project lines on microbiota predictive biomarkers in postoperative ileus and anastomotic leakage, in adult patients.
This session will cover technology for label-free cell isolation. B.sight, a benchtop instrument for automated isolation of prokaryotic cells, single-cell dispensing technology, and how it can be used to isolate single bacteria from heterogeneous samples such as faeces or sputum for subsequent clonal cultivation or single-cell sequencing. The technology could be an ideal tool for isolation and cultivation of potentially unknown microbial species.
What research and development techniques are used to identify the makeup of the microbiome? Discover the emerging technologies used in microbiome drug development, successful collection and utilization of microbiome modulation.
This talk will cover the disruptive approach into engineering the microbiome by delivering genetic circuit expressing CRISP-Cas or other proteins into targeted bacterial populations of the microbiome.
Keynote: The Future of Microbiome Therapeutics
The emerging science of the microbiome is still in its infancy yet it is the driving force behind a transformative scientific revolution. What lies ahead will have broad implications for us as scientists, our companies and academic institutions, our health, and perhaps for our survival. It is worth reflecting on where we are today, how we got here, what we have learned so far, and the limitations of our methods and of our vision. I will present some of the microbiome data from our recent Amazon studies of minimally impacted Yanomami hunter-gatherers, discuss what we are learning about our biological past that is challenging our deeply held ideas about human health.
This session will identify new bio-markers that may serve as disease indicators and to understand biologically-relevant properties of the human gut microbiome, validated measurements that accurately describe various properties of the microbial community are needed, both quantitatively and qualitatively. The availability and compulsory use of the whole stool gut microbiome reference material as well as other reference materials would enable researchers to advance microbiome science through measurement assurance further and faster. While some efforts are currently moving in this direction directed in this area, no clear consensus on methods and criteria for control reagents exists. This session will discuss the current state of the art and novel products in the pipeline as well as suggested uses and scope of applications.
Clinical development and research are advancing at a rapid pace, but multiple questions need to be answered:
Where do human microbiome therapeutics discoveries stand today and what do they mean?
What is next on the horizon for microbiome beyond the gut?
What technologies are being used in clinical stages of microbiome studies?